Neuralink "will start high-volume production of brain-computer interface devices" this year, said Musk in a Tuesday X post. The startup, cofounded by Musk in 2016, is developing technology that enables people to control computers using an implanted microchip. Its initial focus is on helping patients with severe neurological conditions - such as Parkinson's and Alzheimer's, paralysis, or sight impairment - to communicate and regain independence.
Inhibiting LRRK2 both pharmacologically and genetically in mice reduced haloperidol's side effects, suggesting potential strategies to mitigate its harmful impacts on motor function.